Certified by Founder
Lodge
XyloCor Therapeutics, Inc.
start up
United States
- King of Prussia, Pennsylvania
- 09/01/2025
- Series B
- $67,500,000
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.
- Industry Research Services
- Website https://www.xylocor.com/
- LinkedIn https://www.linkedin.com/company/xylocor-therapeutics-inc./
Zero Homes | $16,800,000 | (Feb 19, 2026)
Rainfall Health | $15,000,000 | (Feb 19, 2026)
inKind | $450,000,000 | (Feb 19, 2026)
Sift Biosciences | $3,700,000 | (Feb 19, 2026)
Avantos.ai | $25,000,000 | (Feb 19, 2026)
Korsana Biosciences | $175,000,000 | (Feb 19, 2026)
Vervesemi | $10,000,000 | (Feb 19, 2026)
Efficient Computer | $60,000,000 | (Feb 19, 2026)
DG Matrix | $60,000,000 | (Feb 19, 2026)
Synchrony Medical | $5,000,000 | (Feb 19, 2026)
Dataro | $14,280,000 | (Feb 18, 2026)
The Compression Company | $3,400,000 | (Feb 18, 2026)